P3.09-27 Histopathologic Parameters Define Features of Treatment Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1796
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

ERCC1 Protein Expression Predicts the Response of Cisplatin-Based Neoadjuvant Chemotherapy in Non-Small-Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2008English

Clinical Response to Chemotherapy in Non-Small Cell Lung Carcinoma Patients

International Journal of Research in Medical Sciences
2019English

Oncologic Treatment of Non-Small Cell Lung Cancer Part B: Adjuvant Chemotherapy for Resected Non-Small Cell Lung Carcinoma

2013English

Chemotherapy-Induced Epidermal Growth Factor Receptor Activation Determines Response to Combined Gefitinib/Chemotherapy Treatment in Non-Small Cell Lung Cancer Cells

Molecular Cancer Therapeutics
Cancer ResearchOncology
2006English

Safety and Effectiveness of Localized Lung Resection Combined With Neoadjuvant Chemotherapy in the Treatment of Stage I-Ii Non-Small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2017English

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer

Frontiers in Oncology
Cancer ResearchOncology
2017English

Circulating Nucleosomes Predict the Response to Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2004English

Preoperative Chemotherapy Improves Outcomes in Non-Small Cell Lung Cancer

BMJ
2007English

The Response of Cerebral Metastases in Small Cell Lung Cancer to Systemic Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
1990English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy